Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS)

被引:47
|
作者
El-Salhy, Magdy [1 ,2 ,3 ]
Hausken, Trygve [2 ,3 ]
Hatlebakk, Jan Gunnar [2 ,3 ]
机构
[1] Stord Hosp, Dept Med, Sect Gastroenterol, Box 4000, N-5409 Stord, Norway
[2] Univ Bergen, Dept Clin Med, N-5007 Bergen, Norway
[3] Natl Ctr Funct Gastrointestinal Disorders, N-5021 Bergen, Norway
关键词
abdominal symptoms; dysbiosis; faecal microbiota transplantation; fatigue; IBS; quality of life; QUALITY-OF-LIFE; GASTROINTESTINAL MICROBIOTA; GUT MICROBIOTA; DYSBIOSIS;
D O I
10.3390/nu11061415
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Faecal microbiome transplantation (FMT) appears to be an effective method for treating irritable bowel syndrome (IBS) patients. However, it is not clear if a high transplant dose and/or repeating FMT are/is needed to ensure a response. The present study was undertaken to clarify this matter. Methods: Ten IBS patients who did not respond to a 30-g transplant subsequently received a 60-g transplant into the duodenum via a gastroscope. The patients provided faecal samples before and 1 month after FMT. They completed five questionnaires measuring symptoms, fatigue and quality of life at baseline and then at 2 weeks, 1 month and 3 months after FMT. The dysbiosis index (DI) was measured using the GA-map Dysbiosis Test((R)). Results: Seven patients (70%) responded to the 60-g transplant, with significant clinical improvements in the abdominal symptoms, fatigue and quality of life in 57%, 80% and 67% of these patients. The 60-g transplant also reduced the DI. Conclusion: FMT is an effective treatment for IBS. A high-dose transplant and/or repeated FMT increase the response rate and the intensity of the effects of FMT.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. Authors' reply
    Lahtinen, Perttu
    Jalanka, Jonna
    Hartikainen, Anna
    Mattila, Eero
    Hillila, Markku
    Punkkinen, Jari
    Koskenpato, Jari
    Anttila, Veli-Jukka
    Tillonen, Jyrki
    Satokari, Reetta
    Arkkila, Perttu
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (05) : 925 - 926
  • [42] Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome
    Ianiro, Gianluca
    Eusebi, Leonardo H.
    Black, Christopher J.
    Gasbarrini, Antonio
    Cammarota, Giovanni
    Ford, Alexander C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (03) : 240 - 248
  • [43] Letter: faecal microbiota transplantation for irritable bowel syndrome-which improvements are required? Authors' reply
    Perttu, Lahtinen
    Jonna, Jalanka
    Anna, Hartikainen
    Eero, Mattila
    Markku, Hillila
    Jari, Punkkinen
    Jari, Koskenpato
    Veli-Jukka, Anttila
    Jyrki, Tillonen
    Reetta, Satokari
    Perttu, Arkkila
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (11-12) : 1754 - 1755
  • [44] Fecal microbiota transplantation for managing irritable bowel syndrome
    El-Salhy, Magdy
    Mazzawi, Tarek
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (05) : 439 - 445
  • [45] Correlations between microbiota and metabolites after faecal microbiota transfer in irritable bowel syndrome
    Holster, S.
    Repsilber, D.
    Geng, D.
    Hyotylainen, T.
    Salonen, A.
    Lindqvist, C. M.
    Rajan, S. K.
    de Vos, W. M.
    Brummer, R. J.
    Konig, J.
    BENEFICIAL MICROBES, 2021, 12 (01) : 17 - 30
  • [46] The combined faecal short-chain fatty acids and microbiota profile predicts the response to a gluten-free diet in irritable bowel syndrome (IBS)
    Algera, J.
    Magnusson, M.
    Ohman, L.
    Storsrud, S.
    Simren, M.
    Tornblom, H.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2021, 33
  • [47] Fedotozine increases the threshold of colonic visceral perception in irritable bowel syndrome (IBS) patients.
    Baldi, F
    Brancaccio, ML
    Cappiello, R
    Ghersi, S
    Roda, E
    GASTROENTEROLOGY, 1998, 114 (04) : A715 - A715
  • [48] Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study
    El-Salhy, Magdy
    Hatlebakk, Jan Gunnar
    Gilja, Odd Helge
    Kristoffersen, Anja Brathen
    Hausken, Trygve
    GUT, 2020, 69 (05) : 859 - 867
  • [49] Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones
    El-Salhy, Magdy
    Hatlebakk, Jan Gunnar
    Hausken, Trygve
    NUTRIENTS, 2019, 11 (08)
  • [50] Is fecal microbiota transplantation currently a therapeutic option in patients with irritable bowel syndrome?
    Quera, Rodrigo
    Sedano, Rocio
    Nunez, Paulina
    REVISTA MEDICA DE CHILE, 2020, 148 (05) : 713 - 714